Dexamethasone Sodium Phosphate Injection, USP

Company name

Pfizer Inc

E-mail address of the competent person responsible for the Safety Data Sheet

pfizer-MSDS@pfizer.com

Signal word

DANGER

SECTION 2: Hazards identification

Appearance: Aqueous sterile solution

Signal word

DANGER

Hazard statements

May damage the unborn child. Known Clinical Effects: Clinical use may cause an increase in blood pressure (hypertension). Clinical use has resulted in changes in electrolytes and/or blood chemistry changes. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes. EU Indication of danger: Toxic to reproduction, Category 2 EU Hazard Symbols: EU Risk Phrases: R61 - May cause harm to the unborn child. Australian Hazard Classification

Hazardous Ingredients

Non-Dangerous Goods (NOHSC):

Additional information

For a more detailed discussion of potential health hazards and toxicity see Section 11. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.